Adverse events in cancer patients with sickle cell trait or disease: case reports

Swede, Helen; Andemariam, Biree; Gregorio, David I.; Jones, Beth A.; Braithwaite, Dejana; Rohan, Thomas E.; Stevens, Richard G.

doi:10.1038/gim.2014.105

Cited by 4 publications

(6 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is growing awareness of clinical complications in SCT, 26, 27 and we recently published a multi-case review of major adverse events among cancer patients with Sickle Cell Trait/Disease undergoing systemic therapy. 28 …”

Section: Discussionmentioning

confidence: 99%

Mortality risk from comorbidities independent of triple-negative breast cancer status: NCI-SEER-based cohort analysis

Swede

Sarwar

Magge

et al. 2016

Cancer Causes Control

Self Cite

View full text Add to dashboard Cite

Purpose A comparatively high prevalence of co-morbidities among African-American/Blacks (AA/B) has been implicated in disparate survival in breast cancer. There is a scarcity of data, however, if this effect persists when accounting for the adverse triple-negative breast cancer (TNBC) subtype which occurs at three-fold the rate in AA/B compared to white breast cancer patients. Methods We reviewed charts of 214 white and 202 AA/B breast cancer patients in the NCI-SEER Connecticut Tumor Registry who were diagnosed in 2000-07. We employed the Charlson Co-Morbidity Index (CCI), a weighted 17-item tool to predict risk of death in cancer populations. Cox Survival Analyses estimated hazard ratios (HR) for all-cause mortality in relation to TNBC and CCI adjusting for clinicopathological factors. Results Among patients with SEER-Local Stage, TNBC increased the risk of death (HR=2.18, 95% CI 1.14-4.16), which was attenuated when the CCI score was added to the model (Adj. HR=1.50, 95% CI 0.74-3.01). Conversely, the adverse impact of the CCI score persisted when controlling for TNBC (Adj. HR=1.49, 95% CI 1.29-1.71; per one point increase). Similar patterns were observed in SEER-Regional Stage but estimated HRs were lower. AA/B patients with a CCI score of ≥3 had a significantly higher risk of death compared to AA/B patients without comorbidities (Adj. HR=5.65, 95% CI 2.90-11.02). A lower and non-significant effect was observed for whites with a CCI of ≥3 (Adj. HR=1.90, 95% CI 0.68-5.29). Conclusions Co-morbidities at diagnosis increase risk of death independent of TNBC, and AA/B patients may be disproportionately at risk.

show abstract

Section: Discussionmentioning

confidence: 99%

Mortality risk from comorbidities independent of triple-negative breast cancer status: NCI-SEER-based cohort analysis

Swede

Sarwar

Magge

et al. 2016

Cancer Causes Control

Self Cite

View full text Add to dashboard Cite

show abstract

“…Swede et al examined adverse events experienced by children and adults with SCD or sickle cell trait diagnosed with malignancy by synthesizing relevant case reports. 23 The toxicities experienced were not unique to SCD but instead were adverse events commonly experienced by patients treated for cancer (eg, delayed methotrexate clearance). 23 Case reports describing treatment and complications among patients diagnosed with cooccurring SCD and HL are described in Table 2 .…”

Section: Resultsmentioning

confidence: 99%

Therapy selection for Hodgkin lymphoma in sickle cell disease: balancing risks and benefits

et al. 2023

View full text Add to dashboard Cite

Advances in treatment have reduced mortality from Hodgkin Lymphoma (HL) and made it so greater attention can be focused on minimizing late effects. A variety of risk-adapted treatment regimens exist that prioritize disease presentation, but not patient-specific comorbidities. Herein we describe a patient with sickle cell disease diagnosed with HL and the considerations made in treatment planning to minimize therapy-related acute toxicity and late effects that overlap with the patient's preexisting sickle cell disease complications.

show abstract

“…Many authors put forth hypotheses that intratumoral deformation of erythrocytes was attributed to hypoxic conditions detected in the microvasculature of SCT patients [7,8]. Milosevic et al hypothesized that focal areas of hypoxia in the tumor coupled with long transit times in the abnormal structures of the microcirculation would be sufficient to trigger sickling of vulnerable erythrocytes in SCT carriers; although it is possible that sickling in tumors might have been attributable to ex vivo conditions.…”

Section: Discussionmentioning

confidence: 99%

“…Milosevic et al hypothesized that focal areas of hypoxia in the tumor coupled with long transit times in the abnormal structures of the microcirculation would be sufficient to trigger sickling of vulnerable erythrocytes in SCT carriers; although it is possible that sickling in tumors might have been attributable to ex vivo conditions. High or low temperatures and prolonged drying time of tissue are two such factors that might produce false-positive changes in RBC morphology [8]. Brown et al, however, reported in vivo evidence that sickled RBCs preferentially aggregated in the vasculature of tumor relative to normal tissue based on magnetic resonance imaging scans of radiation-labeled RBCs [9].…”

Section: Discussionmentioning

confidence: 99%

Spontaneous Infarction of Papillary Thyroid Carcinoma in Sickle Cell Trait Patient Leading to Missed Diagnosis on Fine-Needle Aspiration Cytology

Vedita¹,

Meena²,

Dinkar³

2017

IJCR

View full text Add to dashboard Cite

Papillary thyroid carcinoma (PTC) is a common thyroid malignancy in adults and children. With classical microscopic features seen, fine-needle aspiration cytology (FNAC) is a cost-effective and less invasive procedure to diagnose thyroid lesions. Post-FNAC infarction is common in PTC and other solid benign and malignant lesions. Spontaneous infarctions in various organs are seen in sickle cell disease and trait patients in hypoxic conditions. Aspiration of only necrotic material and no distinct microscopic features cause problems in diagnosis. Infarction should be kept in mind while reporting aspirates from sickle cell patients.

show abstract

Adverse events in cancer patients with sickle cell trait or disease: case reports

Cited by 4 publications

References 22 publications

Mortality risk from comorbidities independent of triple-negative breast cancer status: NCI-SEER-based cohort analysis

Mortality risk from comorbidities independent of triple-negative breast cancer status: NCI-SEER-based cohort analysis

Therapy selection for Hodgkin lymphoma in sickle cell disease: balancing risks and benefits

Spontaneous Infarction of Papillary Thyroid Carcinoma in Sickle Cell Trait Patient Leading to Missed Diagnosis on Fine-Needle Aspiration Cytology

Contact Info

Product

Resources

About